AzTrials
AzTrials

Human Cytomegalovirus (HCMV)NCT07477925

Immunological and Virological Prognostic Markers of Human Cytomegalovirus (HCMV) Congenital Infection in Pregnant Women With Primary HCMV Infection.

An observational study of Human Cytomegalovirus (HCMV), run by Fondazione IRCCS Policlinico San Matteo di Pavia at 1 site in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Human cytomegalovirus (HCMV) establishes a lifelong relationship with its host: primary infection is followed by a latency phase with intermittent reactivation episodes, despite a robust, long-lasting immune response. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Human Cytomegalovirus (HCMV)
How many people
90 participants
Where
1 siteItaly
Study dates
3 Oct 2018to 3 Oct 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Pregnant women

Who may be able to join

  • Pregnant women >18 years.
  • HCMV primary infection occurring within 26 weeks of gestation.
  • HCMV primary infection onset within 3 months before enrollment.
  • HCMV pre-conception (non-primary) infection and congenitally infected newborn

Who cannot join

  • HBV, HCV, HIV infection.
  • Known immunodeficiency, immunosuppression or autoimmune disease.
  • Inability to comply with the requirements of the protocol.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Italy1 site, 1 recruiting
  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Lombardy, 27100

    Arsenio Spinillo, MD, 0382 503720, a.spinillo@smatteo.pv.it

    Recruiting

Other trials in Italy

About this study

Human cytomegalovirus (HCMV) establishes a lifelong relationship with its host: primary infection is followed by a latency phase with intermittent reactivation episodes, despite a robust, long-lasting immune response. Primary and non-primary infection (the latter indicating both reactivation and re-infection) is usually asymptomatic in immunocompetent individuals.

Apart from immunocompromised subjects, HCMV is potentially dangerous during pregnancy: the fetus may become infected and develop symptoms at birth or severe long-term sequelae in about 20% of cases (Stagno et al, JAMA 1986; Dollard et al, Rev Med Virol 2007). HCMV is the most common congenital infection with vertical transmission occurring in about 0.64% pregnancies (Cannon \& Davis, BMC Public Health 2005).

Read more

Our studies on the T and B cell response to HCMV suggest that a delayed development of the immune response to HCMV primary infection in pregnant women is associated with virus transmission to fetus (Revello et al., J Infect Dis 2006; Lilleri et al., J Infect Dis 2007; 2008; PLoS ONE 2013; Fornara et al., J Clin Immunol 2011, J Med Virol 2015).

More recently, we observed that women transmitting the virus to the fetus had a higher percentage of "short-term effector" (STE) HCMV-specific CD4+ T cells, while an earlier development of "long-term memory" (LTM) cells was associated with a lower risk of virus transmission to the fetus (Mele et al., PLosOne 2017). LTM are characterized by the expression of the receptor for IL-7 (IL-7R), a cytokine involved in the homeostatic maintenance of memory (and naïve) T cells, whereas STE lack expression of IL-7R and are maintained by antigen stimulation. On the same direction, results of another study showed that the earlier development of memory-like CD4+ T cells specific for the pp65 antigen of HCMV (i.e. T cells able to proliferate in vitro in response to the antigen) as determined by a culture ELISPOT is associated with a lower risk of HCMV transmission (Fornara et al., CID 2017).

The limitation of our study of LTM vs STE resides on the fine but cumbersome technique applied, which was based on sorting of the two T-cell subsets and subsequent 3-weeks expansion of multiple T-cell culture replicates (T-cell library), before testing their specificity for HCMV (Geiger et al., J Exp Med 2009). However, our preliminary results show that LTM and STE HCMV-specific T cells can be detected also by direct ex vivo stimulation of T cells and simultaneous determination of IFNγ production (HCMV-specificity) and IL-7R expression (T-cell phenotype) by flow cytometry.

The aims of the present study is to determine the prognostic performance of the combination of different parameters of HCMV-specific T cell response (CD45RA re-expression, LTM phenotype, IL-2 production and lymphoproliferation), in order to be used in the clinical practice to assess the risk of HCMV transmission to the fetus after maternal primary infection. In addition, we will explore whether the presence of memory-like (i.e. expandable) CD4+ T cells able to proliferate in response to other individual HCMV antigens are associated with the risk of virus transmission to the fetus.

HCMV vaccine is actively sought and several candidates are being proposed (Wang \& Fu, Curr Opin Virol 2014) and the definition of immune parameters associated with protection against non-primary infection and virus transmission is mandatory to analyze the effectiveness of different vaccines being developed.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. detection of immune parameters associated with the risk of HCMV transmission

    The main objective of the study is to detect immune parameters associated with the risk of HCMV transmission to the fetus after maternal primary infection.

    Measured: up to 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Mar 2026
  2. Study start3 Oct 2018
  3. Primary completion3 Oct 2026 (estimated)
  4. Study completion3 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07477925
Sponsor's protocol ID
HCMV transmission markers
Status last verified
Mar 2026
First submitted
12 Mar 2026
Last updated
17 Mar 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Human Cytomegalovirus (HCMV), run by Fondazione IRCCS Policlinico San Matteo di Pavia at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

detection of immune parameters associated with the risk of HCMV transmission (time frame: up to 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in